Start Date
2022
Description
Immune checkpoint inhibitor therapy was designed to reinvigorate immune cells to bind and kill cancer cells. However, the treatment that was intended to help patients resulted in hyper progressive disease (when the tumor shows accelerated growth, leading to an explosion of tumor growth in a short period of time). We searched for a particular gene that could function as a biomarker for hyperprogression. Upon inspecting tumor samples, we discovered a biomarker called CYP1A1. We thought to test if a tumor that expressed high levels of endogenous CYP1A1, treated with immunotherapy, ultimately led to hyper progression. Every step of the project was preliminary; thus, we did not have an experimental system to test the hypothesis. So, I helped developing the experimental system.
Recommended Citation
Kim, Hyeon Jin; Jones, Peter; Jang, Josh; and Kulchycki, Justin, "Exploring the Role of AHR Activation in Bladder Cancer Models" (2022). Summer Research. 20.
https://digitalcommons.calvin.edu/summer_research/2022/Posters/20
Included in
Exploring the Role of AHR Activation in Bladder Cancer Models
Immune checkpoint inhibitor therapy was designed to reinvigorate immune cells to bind and kill cancer cells. However, the treatment that was intended to help patients resulted in hyper progressive disease (when the tumor shows accelerated growth, leading to an explosion of tumor growth in a short period of time). We searched for a particular gene that could function as a biomarker for hyperprogression. Upon inspecting tumor samples, we discovered a biomarker called CYP1A1. We thought to test if a tumor that expressed high levels of endogenous CYP1A1, treated with immunotherapy, ultimately led to hyper progression. Every step of the project was preliminary; thus, we did not have an experimental system to test the hypothesis. So, I helped developing the experimental system.